Long-term safety of dichloroacetate in congenital lactic acidosis.
about
Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series)Increasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular AscorbateEmerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertensionMitochondrial targeting by dichloroacetate improves outcome following hemorrhagic shock.Treatment of mitochondrial disorders.Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in childrenChloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans.Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.Potential compounds for the treatment of mitochondrial disease.E4F1 controls a transcriptional program essential for pyruvate dehydrogenase activityDichloroacetate treatment improves mitochondrial metabolism and reduces brain injury in neonatal miceDichloroacetate modulates cytokines toward T helper 1 function via induction of the interleukin-12-interferon-γ pathway.Elevated cerebral lactate: Implications in the pathogenesis of hepatic encephalopathy.Metabolic modulation of cancer: a new frontier with great translational potential.Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease.Pharmacogenetic considerations with dichloroacetate dosing.Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.Metabolic support for the heart: complementary therapy for heart failure?A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression.Therapies for mitochondrial diseases and current clinical trials.Targeting HIF-1α/PDK1 Axis by Dichloroacetate (DCA) Suppresses Bleomycin-induced Pulmonary Fibrosis.Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients.Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer.Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children.Pyruvate dehydrogenase kinase 2 and 4 gene deficiency attenuates nociceptive behaviors in a mouse model of acute inflammatory pain.A Comparative QSAR Analysis, Molecular Docking and PLIF Studies of Some N-arylphenyl-2, 2-Dichloroacetamide Analogues as Anticancer Agents.
P2860
Q26772286-763FBDF5-D429-43EA-A2F3-AAAE53DD6FE5Q27021794-FD1C301F-565E-4F2F-BC08-6CFA68AA6EC3Q28083183-231DC8F5-DF13-44DD-8542-46F04EEE4A8DQ33752927-E55AC835-2C79-496D-BEB1-FE495BD03243Q33794684-A116958C-A9A5-41AC-A9C3-ECAAC8F8D896Q34771992-8FE25A84-3FF7-4A02-AA43-858C12F19B85Q35684236-6E56B1F0-3EAC-4B49-A9C1-809B70A98CC8Q35684292-A10DB17D-FDA7-41E1-A9D7-EB542404F821Q35847813-F6BC90E6-7B1D-4F02-AC32-22576304EB3DQ37304882-6C68ACD5-05DC-401E-A0EF-75D90F0AF8B0Q37362500-14389130-FF65-438E-8A0C-6CA43853584DQ37582487-0A6518E1-84F6-4D77-BCB0-140419DBEF43Q38219286-A9A5BF5D-6FA6-4F93-8DEF-9E047AFD9A2CQ38317294-1003D192-8F9C-4204-B452-97E1D6C865EAQ38357534-6BBB593F-B5A3-4DA2-9A08-FA581F4CE8A0Q38824892-774E9C3E-35C1-4BF5-AC24-E5CF24B883FFQ38988403-0933A19C-456C-4600-9156-D8E3016C33ADQ38998576-0F6CDE36-636E-48E2-9276-9F5784E4FAF2Q39030297-859E0953-3D19-43CF-9F51-F05F0FB13F75Q41299961-E70FFE96-69F4-46E9-ACD1-E3A9A7D66533Q45872396-23C5B317-960F-4EE0-9B65-203068EC9D5BQ46792366-72DFAB8F-A150-48DB-AA4F-F10D901FF90BQ47410087-1D460881-7AA6-4687-A9F4-8B861D416DF6Q47615969-48A95081-9377-4241-977C-AFA7E3DB1A00Q47978860-1BF461CC-9976-478D-BDAA-298ABDAFCD15Q48867969-BB60C286-2769-4D4C-B3D4-5D1F1217BF33Q52382378-A3B21973-5B2A-4E8D-8689-810D5B020E34
P2860
Long-term safety of dichloroacetate in congenital lactic acidosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term safety of dichloroacetate in congenital lactic acidosis.
@en
Long-term safety of dichloroacetate in congenital lactic acidosis.
@nl
type
label
Long-term safety of dichloroacetate in congenital lactic acidosis.
@en
Long-term safety of dichloroacetate in congenital lactic acidosis.
@nl
prefLabel
Long-term safety of dichloroacetate in congenital lactic acidosis.
@en
Long-term safety of dichloroacetate in congenital lactic acidosis.
@nl
P2093
P2860
P1476
Long-term safety of dichloroacetate in congenital lactic acidosis.
@en
P2093
Albert L Shroads
Alicia Lew
Bonnie S Coats
Meena N Shankar
Monica Abdelmalak
Peter W Stacpoole
Richard E Neiberger
Ryan Ramezani
S H Subramony
Taimour Langaee
P2860
P304
P356
10.1016/J.YMGME.2013.03.019
P577
2013-04-06T00:00:00Z